Full Press Release Details
Health In Tech Announces Fourth Quarter and
Full Year 2025 Financial Results
Stuart, FL., March 25, 2026 /PRNewswire/ -
Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company,
today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Financial Highlights for the Full Year 2025
and Fourth Quarter of 2025:
Health In Tech expects full-year 2026 revenue
to be in the range of $45 million to $50 million, representing year-over-year growth of approximately 35% to 50%. This outlook is based
on management's current expectations and assumptions, including continued strong demand for the Company's AI-enabled underwriting
marketplace across the self-funded health insurance segment and successful deployment of new features. Actual results may differ materially
due to risks and uncertainties described in Health In Tech's filings with the SEC.
The Company expects continued growth driven by expanding
engagement across its distribution network and the full deployment of new features launched in January 2026. Unlike the traditional insurance
industry, where new product and service implementations typically require one to two years, Health In Tech's AI-driven platform
enables new capabilities to be developed and deployed within approximately one to two quarters. This accelerated development cycle provides
a meaningful competitive advantage, allowing the Company to respond quickly to broker and client demand, continuously enhance its marketplace
offerings, and scale its technology platform more efficiently than traditional market participants.
Tim Johnson, Chief Executive Officer of
Health In Tech, commented, "2025 was a defining year of disciplined execution and measurable platform scale for
Health In Tech. We strengthened our AI-enabled underwriting marketplace, expanded carrier, broker, and TPA integrations, and further
automated core insurance workflows to drive efficiency and margin scalability. We extended underwriting capabilities into larger
employer segments and continued enhancing our technology architecture to support enterprise-level throughput across the
approximately $300 billion U.S. claims administration market. Most importantly, we translated operational progress into financial
performance, delivering 71% year-over-year revenue growth."
Mr. Johnson continued, "As we enter 2026, our
focus is on advancing a fully integrated marketplace model that expands beyond underwriting to include additional services such as claims
administration and administrative cost-containment solutions. Building on years of assembling specialized healthcare vendors and service
providers essential to self-funded plans, we enhanced our platform in January 2026 to offer more than 100 pre-configured, customized stop-loss
programs tailored at the broker-agency level. This structured program architecture enables agencies to align standardized offerings with
target employer segments, empowering brokers to deliver execution-ready solutions with greater speed, consistency, and operational efficiency.
The result is shorter sales cycles, improved conversion visibility, and scalable distribution leverage, while maintaining the flexibility
to customize for employer-specific needs.
"In the first half of 2026, we expect to
complete market testing of our Three-Year Rate stabilization program, designed to provide cost stability and predictability for eligible
employer groups. We also plan to initiate beta testing of a new data-driven solution that integrates physiological data and claims data
to generate actionable value insights. Together, these initiatives reflect our strategy of layering incremental, high-value services onto
an already commercialized and scalable platform to drive durable growth and increasing operating leverage."
Key Developments in Q1 2026
Conference Call Details
Health In Tech will host a conference call to
discuss the financial results for the fourth quarter and full year of 2025 on March 25, 2026, at 5:00 p.m. (ET). To participate in our
live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).
live audio webcast will be available via the Investor Relations page of Health In Tech's website at https://healthintech.com/.
A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and
will remain available for approximately 90 days.
Non-GAAP Financial Information
This release presents Adjusted EBITDA, a non-GAAP
financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted
in the United States of America ("GAAP"). Management uses Adjusted EBITDA to provide investors with additional insight into
operational performance and to facilitate comparison with other companies in the industry. Adjusted EBITDA should not be considered an
alternative to net income, operating income, or other GAAP measures. A reconciliation of historical non-GAAP financial information to
the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.
Use of Forward-Looking Statements
Certain statements in this press release are forward-looking
statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements may include estimates or expectations about Health In Tech's possible or assumed operational results, financial condition,
business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In
some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "design,"
"target," "aim," "hope," "expect," "could," "intend," "plan," "anticipate,"
"estimate," "believe," "continue," "predict," "project," "potential," "goal,"
or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech's
future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech's actual
results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements
because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech's control
and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement
reflects Health In Tech's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions
relating to Health In Tech's operations, results of operations, growth strategy and liquidity.
About Health In Tech
Health In Tech, Inc. (Nasdaq: "HIT")
is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through
vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales
and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs) and third-party administrators ("TPAs").
Health In Tech's platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for
employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims
administration and reporting integration. Learn more at healthintech.com.
Health In Tech, Inc.
Consolidated Statements of Operations
| Three Months Ended December 31, | Fiscal Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues | ||||||||||||||||
| Revenues from underwriting modeling (ICE) | $ | 1,032,381 | $ | 1,697,080 | $ | 6,864,545 | $ | 6,649,271 | ||||||||
| Revenues from fees | 6,476,204 | 3,207,484 | 26,462,966 | 12,841,635 | ||||||||||||
| SMR | 6,476,204 | 2,470,284 | 26,462,966 | 9,849,300 | ||||||||||||
| HI Card | - | 737,200 | - | 2,992,335 | ||||||||||||
| Total revenues | 7,508,585 | 4,904,564 | 33,327,511 | 19,490,906 | ||||||||||||
| Cost of revenues | 3,379,942 | 1,107,173 | 12,389,783 | 4,051,439 | ||||||||||||
| Gross profit | 4,128,643 | 3,797,391 | 20,937,728 | 15,439,467 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Sales and marketing expenses | 906,206 | 632,060 | 4,185,766 | 3,158,257 | ||||||||||||
| General and administrative expenses | 3,180,137 | 2,848,014 | 13,654,262 | 8,477,407 | ||||||||||||
| Research and development expenses | 213,113 | 633,653 | 1,569,262 | 2,813,899 | ||||||||||||
| Total operating expenses | 4,299,456 | 4,113,727 | 19,409,290 | 14,449,563 | ||||||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 104,659 | 28,774 | 409,922 | 122,885 | ||||||||||||
| Interest expenses | - | - | - | (495,000 | ) | |||||||||||
| Other income | - | 114,055 | 118,399 | 271,211 | ||||||||||||
| Other expense | (377,587 | ) | 62,759 | (382,587 | ) | - | ||||||||||
| Total other income (expense), net | (272,928 | ) | 205,588 | 145,734 | (100,904 | ) | ||||||||||
| Income (loss) before income tax expense | $ | (443,741 | ) | $ | (110,748 | ) | $ | 1,674,172 | $ | 889,000 | ||||||
| Provision for income taxes | 141,184 | (33,404 | ) | (395,330 | ) | (218,523 | ) | |||||||||
| Net income (loss) | $ | (302,557 | ) | $ | (144,152 | ) | $ | 1,278,842 | $ | 670,477 | ||||||
| Net income per share | ||||||||||||||||
| Basic | $ | (0.01 | ) | $ | (0.00 | ) | $ | 0.02 | $ | 0.01 | ||||||
| Diluted | $ | (0.01 | ) | $ | (0.00 | ) | $ | 0.02 | $ | 0.01 | ||||||
| Weighted average common stocks outstanding | ||||||||||||||||
| Basic | 56,908,999 | 52,047,723 | 55,843,821 | 51,839,329 | ||||||||||||
| Diluted | 58,635,562 | 54,662,931 | 57,742,798 | 53,662,677 |
Health In Tech, Inc.
Consolidated Balance Sheets
| December 31, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 7,669,754 | $ | 7,849,248 | ||||
| Accounts receivable, net | 756,288 | 1,647,103 | ||||||
| Loans receivable, net | 815,995 | - | ||||||
| Other receivables, net | 3,467,814 | 500,252 | ||||||
| Deferred offering costs | 170,977 | - | ||||||
| Prepaid expenses and other current assets | 3,280,148 | 787,161 | ||||||
| Total current assets | 16,160,976 | 10,783,764 | ||||||
| Non-current assets | ||||||||
| Software | 6,530,894 | 3,962,461 | ||||||
| Loans receivable, net | - | 815,995 | ||||||
| Operating lease - right of use assets | 139,940 | 206,269 | ||||||
| Long-term prepaid expenses | 258,151 | - | ||||||
| Total non-current assets | 6,928,985 | 4,984,725 | ||||||
| Total assets | $ | 23,089,961 | $ | 15,768,489 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 4,188,811 | $ | 1,858,840 | ||||
| Income taxes payable | - | 205,253 | ||||||
| Operating lease liabilities - current | 76,195 | 66,881 | ||||||
| Other current liability | 891,598 | - | ||||||
| Total current liabilities | 5,156,604 | 2,130,974 | ||||||
| Non-current liabilities | ||||||||
| Deferred tax liabilities | 757,675 | 328,676 | ||||||
| Operating lease liabilities - non-current | 63,617 | 139,811 | ||||||
| Total non-current liabilities | 821,292 | 468,487 | ||||||
| Total liabilities | 5,977,896 | 2,599,461 | ||||||
| Stockholders' equity | ||||||||
| Common stock, $0.001 par value; Class A Common stock 150,000,000 shares authorized 46,006,000 and 42,914,870 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 46,006 | 42,915 | ||||||
| Common stock, $0.001 par value; Class B Common stock 50,000,000 shares authorized, 11,700,000 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 11,700 | 11,700 | ||||||
| Additional paid-in capital | 11,834,121 | 9,173,017 | ||||||
| Retained earnings | 5,220,238 | 3,941,396 | ||||||
| Total stockholders' equity | 17,112,065 | 13,169,028 | ||||||
| Total liabilities and stockholders' equity | $ | 23,089,961 | $ | 15,768,489 |
Health In Tech, Inc.
Consolidated Statements of Cash Flows
| Fiscal Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income | $ | 1,278,842 | $ | 670,477 | ||||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||
| Bad debt expense (recovery) | (16,234 | ) | 1,878 | |||||
| Amortization expense | 900,577 | 541,141 | ||||||
| Provision for refund liability | 3,891,598 | - | ||||||
| Provision for credit losses on other receivables | 377,587 | - | ||||||
| Deferred tax expenses (benefits) | 428,999 | (93,304 | ) | |||||
| Amortization of debt discount | - | 495,000 | ||||||
| Interest income | (64,000 | ) | (63,996 | ) | ||||
| Stock-based compensation expense | 1,570,419 | 468,489 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 907,049 | 586,685 | ||||||
| Other receivables | (3,345,149 | ) | 1,180,848 | |||||
| Prepaid expenses and other assets | (1,948,184 | ) | (514,242 | ) | ||||
| Operating lease right of use assets and liabilities, net | (551 | ) | 1,889 | |||||
| Accounts payable and accrued expenses | 2,358,113 | (851,963 | ) | |||||
| Income taxes payable | (205,253 | ) | (246,693 | ) | ||||
| Other current liabilities | (3,000,000 | ) | - | |||||
| Net cash provided by operating activities | 3,133,813 | 2,176,209 | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Development of software | (3,189,921 | ) | (900,755 | ) | ||||
| Interest received from loans receivable | 64,000 | 64,000 | ||||||
| Net cash used in investing activities | (3,125,921 | ) | (836,755 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions | - | 8,214,000 | ||||||
| Proceeds from stock option exercises | 23,430 | - | ||||||
| Payments of deferred offering costs | (210,816 | ) | (1,975,556 | ) | ||||
| Repayments of notes payable | - | (2,145,000 | ) | |||||
| Net cash provided by (used in) financing activities | (187,386 | ) | 4,093,444 | |||||
| Increase (decrease) in cash and cash equivalents | (179,494 | ) | 5,432,898 | |||||
| Cash and cash equivalents, beginning of year | 7,849,248 | 2,416,350 | ||||||
| Cash and cash equivalents, end of year | 7,669,754 | 7,849,248 | ||||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for interest | $ | - | $ | - | ||||
| Cash paid for income taxes | $ | 830,726 | $ | 558,521 | ||||
| Summary of noncash investing and financing activities: | ||||||||
| Accrued deferred offering costs included in accounts payable and accrued expenses | $ | - | $ | 39,839 | ||||
| Accrued development of software included in accounts payable and accrued expenses | $ | 38,363 | $ | 50,000 | ||||
| Reclassification of deferred offering costs to additional paid-in capital upon initial public offering | $ | - | $ | 2,277,164 | ||||
| Stock-based compensation capitalized for software development | $ | 290,726 | $ | - |
Health In Tech, Inc.
Reconciliation of GAAP (Net Income) to Non-GAAP
Financial Measure (Adjusted EBITDA)
| Three Months Ended December 31, | Fiscal Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net income | (302,557 | ) | (144,152 | ) | 1,278,842 | 670,477 | ||||||||||
| Interest (income) expenses | (104,659 | ) | (28,774 | ) | (409,922 | ) | 372,115 | |||||||||
| Amortization expense | 410,630 | 135,983 | 900,577 | 541,141 | ||||||||||||
| Income tax expense | (141,184 | ) | 33,404 | 395,330 | 218,523 | |||||||||||
| Stock-based compensation expense | 76,733 | 468,489 | 1,570,419 | 468,489 | ||||||||||||
| Provision for credit losses on other receivables | 377,587 | - | 377,587 | - | ||||||||||||
| Total net adjustments | 619,107 | 609,102 | 2,833,991 | 1,600,268 | ||||||||||||
| Adjusted EBITDA | 316,550 | 464,950 | 4,112,833 | 2,270,745 |
Health In Tech Investor Relations
Devin Sullivan, Managing Director